President Donald Trump signed an executive order that claims to force Big Medicine to lower prescription drug prices paid by ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

Many patients may have to switch obesity drugs now that CVS Caremark opted to stop offering tirzepatide (Zepbound) in favor ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...